Katie Dahlstrom

Senior Vice President of Clinical Development Strategy & Operations

Katie Dahlstrom is a Senior Vice President of Development Strategy & Operations at Raven. Katie leads the Blackbird team, inclusive of Swiftbridge Clinical in China, RA Capital’s development accelerator. Katie is passionate about finding fit-for-purpose solutions to difficult challenges, building high performing teams and development frameworks for newcos and implementing best practices into RA Capital Management’s portfolio companies. Prior to RA, Katie was Vice President of Clinical Development Operations at Theseus Pharmaceuticals where she built the development operations organization and executed the early-stage oncology portfolio. Before Theseus, Katie held increasing levels of responsibility in Clinical Operations at Agios Pharmaceuticals where she oversaw the operational execution of the TIBSOVO® (ivosidenib) program for R/R AML from IND to NDA and the PYRUKIND® (mitapivat) program for pyruvate kinase deficiency from Phase 2 to NDA. Katie has prior clinical operations experience from Takeda Oncology and pharmacovigilance experience from Genzyme, a Sanofi Company. Katie holds a BS in Biology from Stonehill College and an MA in Clinical Investigation from Boston University Medical School.